logo
Breadcrumbs Image

Non Insulin Therapies for Diabetes Market

Non Insulin Therapies for Diabetes Market

Global Non-Insulin Therapies for Diabetes Market Research Report 2021 Professional Edition


Date: Apr-2021 | Id: MACRC-45430 | Geographical Scope: Global | Publisher: HNY Research

The research team projects that the Non-Insulin Therapies for Diabetes market size will grow from XXX in 2020 to XXX by 2027, at an estimated CAGR of XX. The base year considered for the study is 2020, and the market size is projected from 2020 to 2027.

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:
GSK
Emisphere
Intarcia Therapeutics
Eli Lilly
Novo Nordisk
Sumitomo Dainippon Pharma
Takeda
Jiangsu Hansoh Pharmaceutical
Servier
Uni-Bio Science Group
Eurofarma
SatRx
3SBio
Jiangsu Hengrui Medicine
Geropharm
Luye Pharma Group
Merck
Pfizer
Alkem Labs
Dong-A Pharmaceutical

By Type
Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones

By Application
Hospital Pharmacy
Retail Pharmacies
Online Pharmacy
Others

By Regions/Countries:
North America
United States
Canada
Mexico

East Asia
China
Japan
South Korea

Europe
Germany
United Kingdom
France
Italy
Russia
Spain
Netherlands
Switzerland
Poland

South Asia
India
Pakistan
Bangladesh

Southeast Asia
Indonesia
Thailand
Singapore
Malaysia
Philippines
Vietnam
Myanmar

Middle East
Turkey
Saudi Arabia
Iran
United Arab Emirates
Israel
Iraq
Qatar
Kuwait
Oman

Africa
Nigeria
South Africa
Egypt
Algeria
Morocoo

Oceania
Australia
New Zealand

South America
Brazil
Argentina
Colombia
Chile
Venezuela
Peru
Puerto Rico
Ecuador

Rest of the World
Kazakhstan

Points Covered in The Report
The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years data history and forecast.
The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.
Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.
The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global  market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Non-Insulin Therapies for Diabetes 2016-2021, and development forecast 2022-2027 including industries, major players/suppliers worldwide and market share by regions, with company and product introduction, position in the market including their market status and development trend by types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with base year as 2020.

Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2021 & Sales by Product Types.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2022-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its production, consumption, import & export, sales volume & revenue forecast.
Market Analysis by Product Type: The report covers majority Product Types in the Non-Insulin Therapies for Diabetes Industry, including its product specifcations by each key player, volume, sales by Volume and Value (M USD).
Markat Analysis by Application Type: Based on the Non-Insulin Therapies for Diabetes Industry and its applications, the market is further sub-segmented into several major Application of its industry. It provides you with the market size, CAGR & forecast by each industry applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and <b>Drivers:</b> Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report will provide with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

COVID-19 Impact
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Non-Insulin Therapies for Diabetes market in 2021. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Get Started with Request an Overview
Get Started with Download Brochure
Get Started with Request Methodology
Get Started with Share Customization
Get Started with Submit RFP
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non-Insulin Therapies for Diabetes Revenue
1.4 Market Analysis by Type
1.4.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Alpha-glucosidase Inhibitors
1.4.3 Amylin Agonists
1.4.4 Biguanides
1.4.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
1.4.6 Glinides / Meglitinides
1.4.7 GLP-1 Analogs / GLP-1 Agonists
1.4.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
1.4.9 Sulfonylureas
1.4.10 Thiazolidinediones
1.5 Market by Application
1.5.1 Global Non-Insulin Therapies for Diabetes Market Share by Application: 2022-2027
1.5.2 Hospital Pharmacy
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacy
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Non-Insulin Therapies for Diabetes Market
1.8.1 Global Non-Insulin Therapies for Diabetes Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Non-Insulin Therapies for Diabetes Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Non-Insulin Therapies for Diabetes Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Non-Insulin Therapies for Diabetes Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Non-Insulin Therapies for Diabetes Sales Volume Market Share by Region (2016-2021)
3.2 Global Non-Insulin Therapies for Diabetes Sales Revenue Market Share by Region (2016-2021)
3.3 North America Non-Insulin Therapies for Diabetes Sales Volume
3.3.1 North America Non-Insulin Therapies for Diabetes Sales Volume Growth Rate (2016-2021)
3.3.2 North America Non-Insulin Therapies for Diabetes Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Non-Insulin Therapies for Diabetes Sales Volume
3.4.1 East Asia Non-Insulin Therapies for Diabetes Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Non-Insulin Therapies for Diabetes Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Non-Insulin Therapies for Diabetes Sales Volume (2016-2021)
3.5.1 Europe Non-Insulin Therapies for Diabetes Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Non-Insulin Therapies for Diabetes Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Non-Insulin Therapies for Diabetes Sales Volume (2016-2021)
3.6.1 South Asia Non-Insulin Therapies for Diabetes Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Non-Insulin Therapies for Diabetes Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Non-Insulin Therapies for Diabetes Sales Volume (2016-2021)
3.7.1 Southeast Asia Non-Insulin Therapies for Diabetes Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Non-Insulin Therapies for Diabetes Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Non-Insulin Therapies for Diabetes Sales Volume (2016-2021)
3.8.1 Middle East Non-Insulin Therapies for Diabetes Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Non-Insulin Therapies for Diabetes Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Non-Insulin Therapies for Diabetes Sales Volume (2016-2021)
3.9.1 Africa Non-Insulin Therapies for Diabetes Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Non-Insulin Therapies for Diabetes Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Non-Insulin Therapies for Diabetes Sales Volume (2016-2021)
3.10.1 Oceania Non-Insulin Therapies for Diabetes Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Non-Insulin Therapies for Diabetes Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Non-Insulin Therapies for Diabetes Sales Volume (2016-2021)
3.11.1 South America Non-Insulin Therapies for Diabetes Sales Volume Growth Rate (2016-2021)
3.11.2 South America Non-Insulin Therapies for Diabetes Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Non-Insulin Therapies for Diabetes Sales Volume (2016-2021)
3.12.1 Rest of the World Non-Insulin Therapies for Diabetes Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Non-Insulin Therapies for Diabetes Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Non-Insulin Therapies for Diabetes Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Non-Insulin Therapies for Diabetes Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Non-Insulin Therapies for Diabetes Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Non-Insulin Therapies for Diabetes Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Non-Insulin Therapies for Diabetes Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Non-Insulin Therapies for Diabetes Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Non-Insulin Therapies for Diabetes Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Non-Insulin Therapies for Diabetes Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Non-Insulin Therapies for Diabetes Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Non-Insulin Therapies for Diabetes Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Non-Insulin Therapies for Diabetes Sales Volume Market Share by Type (2016-2021)
14.2 Global Non-Insulin Therapies for Diabetes Sales Revenue Market Share by Type (2016-2021)
14.3 Global Non-Insulin Therapies for Diabetes Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Non-Insulin Therapies for Diabetes Consumption Volume by Application (2016-2021)
15.2 Global Non-Insulin Therapies for Diabetes Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Non-Insulin Therapies for Diabetes Business
16.1 GSK
16.1.1 GSK Company Profile
16.1.2 GSK Non-Insulin Therapies for Diabetes Product Specification
16.1.3 GSK Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Emisphere
16.2.1 Emisphere Company Profile
16.2.2 Emisphere Non-Insulin Therapies for Diabetes Product Specification
16.2.3 Emisphere Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 Intarcia Therapeutics
16.3.1 Intarcia Therapeutics Company Profile
16.3.2 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product Specification
16.3.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Eli Lilly
16.4.1 Eli Lilly Company Profile
16.4.2 Eli Lilly Non-Insulin Therapies for Diabetes Product Specification
16.4.3 Eli Lilly Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Novo Nordisk
16.5.1 Novo Nordisk Company Profile
16.5.2 Novo Nordisk Non-Insulin Therapies for Diabetes Product Specification
16.5.3 Novo Nordisk Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Sumitomo Dainippon Pharma
16.6.1 Sumitomo Dainippon Pharma Company Profile
16.6.2 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product Specification
16.6.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Takeda
16.7.1 Takeda Company Profile
16.7.2 Takeda Non-Insulin Therapies for Diabetes Product Specification
16.7.3 Takeda Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Jiangsu Hansoh Pharmaceutical
16.8.1 Jiangsu Hansoh Pharmaceutical Company Profile
16.8.2 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product Specification
16.8.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 Servier
16.9.1 Servier Company Profile
16.9.2 Servier Non-Insulin Therapies for Diabetes Product Specification
16.9.3 Servier Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.10 Uni-Bio Science Group
16.10.1 Uni-Bio Science Group Company Profile
16.10.2 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product Specification
16.10.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.11 Eurofarma
16.11.1 Eurofarma Company Profile
16.11.2 Eurofarma Non-Insulin Therapies for Diabetes Product Specification
16.11.3 Eurofarma Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.12 SatRx
16.12.1 SatRx Company Profile
16.12.2 SatRx Non-Insulin Therapies for Diabetes Product Specification
16.12.3 SatRx Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.13 3SBio
16.13.1 3SBio Company Profile
16.13.2 3SBio Non-Insulin Therapies for Diabetes Product Specification
16.13.3 3SBio Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.14 Jiangsu Hengrui Medicine
16.14.1 Jiangsu Hengrui Medicine Company Profile
16.14.2 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product Specification
16.14.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.15 Geropharm
16.15.1 Geropharm Company Profile
16.15.2 Geropharm Non-Insulin Therapies for Diabetes Product Specification
16.15.3 Geropharm Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.16 Luye Pharma Group
16.16.1 Luye Pharma Group Company Profile
16.16.2 Luye Pharma Group Non-Insulin Therapies for Diabetes Product Specification
16.16.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.17 Merck
16.17.1 Merck Company Profile
16.17.2 Merck Non-Insulin Therapies for Diabetes Product Specification
16.17.3 Merck Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.18 Pfizer
16.18.1 Pfizer Company Profile
16.18.2 Pfizer Non-Insulin Therapies for Diabetes Product Specification
16.18.3 Pfizer Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.19 Alkem Labs
16.19.1 Alkem Labs Company Profile
16.19.2 Alkem Labs Non-Insulin Therapies for Diabetes Product Specification
16.19.3 Alkem Labs Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.20 Dong-A Pharmaceutical
16.20.1 Dong-A Pharmaceutical Company Profile
16.20.2 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product Specification
16.20.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Non-Insulin Therapies for Diabetes Manufacturing Cost Analysis
17.1 Non-Insulin Therapies for Diabetes Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Non-Insulin Therapies for Diabetes
17.4 Non-Insulin Therapies for Diabetes Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Non-Insulin Therapies for Diabetes Distributors List
18.3 Non-Insulin Therapies for Diabetes Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Non-Insulin Therapies for Diabetes (2022-2027)
20.2 Global Forecasted Revenue of Non-Insulin Therapies for Diabetes (2022-2027)
20.3 Global Forecasted Price of Non-Insulin Therapies for Diabetes (2016-2027)
20.4 Global Forecasted Production of Non-Insulin Therapies for Diabetes by Region (2022-2027)
20.4.1 North America Non-Insulin Therapies for Diabetes Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Non-Insulin Therapies for Diabetes Production, Revenue Forecast (2022-2027)
20.4.3 Europe Non-Insulin Therapies for Diabetes Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Non-Insulin Therapies for Diabetes Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Non-Insulin Therapies for Diabetes Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Non-Insulin Therapies for Diabetes Production, Revenue Forecast (2022-2027)
20.4.7 Africa Non-Insulin Therapies for Diabetes Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Non-Insulin Therapies for Diabetes Production, Revenue Forecast (2022-2027)
20.4.9 South America Non-Insulin Therapies for Diabetes Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Non-Insulin Therapies for Diabetes Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Non-Insulin Therapies for Diabetes by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Non-Insulin Therapies for Diabetes by Country
21.2 East Asia Market Forecasted Consumption of Non-Insulin Therapies for Diabetes by Country
21.3 Europe Market Forecasted Consumption of Non-Insulin Therapies for Diabetes by Countriy
21.4 South Asia Forecasted Consumption of Non-Insulin Therapies for Diabetes by Country
21.5 Southeast Asia Forecasted Consumption of Non-Insulin Therapies for Diabetes by Country
21.6 Middle East Forecasted Consumption of Non-Insulin Therapies for Diabetes by Country
21.7 Africa Forecasted Consumption of Non-Insulin Therapies for Diabetes by Country
21.8 Oceania Forecasted Consumption of Non-Insulin Therapies for Diabetes by Country
21.9 South America Forecasted Consumption of Non-Insulin Therapies for Diabetes by Country
21.10 Rest of the world Forecasted Consumption of Non-Insulin Therapies for Diabetes by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer

Add to Cart

Single User

$ 2890.00

Site License

$ 4335.00

Enterprisewide

$ 5780.00